Name

BioSun Pharmed

Legal name

Biosun Pharmed Pharmaceutical Company

Website

https://en.biosunpharmed.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Biosimilar pharmaceuticals
• Vaccine manufacturing
• Peptide drugs
• Monoclonal antibody production
• Biopharmaceutical manufacturing

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Biosun Pharmed generates revenue through the sale of biosimilar drugs, peptide medications, and vaccines to domestic healthcare providers, hospitals, clinics, and government health programs. The company supplies approximately 6 million annual doses of the Pentavalent vaccine to Iran's national immunization program and sells products at significantly lower prices than imported alternatives (e.g., Gardisun at less than half the price of imported HPV vaccines). MS patients under insurance coverage pay only 5–10% of the drug cost.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

BioSun Pharmed manufactures biosimilar drugs, vaccines, monoclonal antibodies, and peptide medications at its plants within the Barekat Pharmaceutical Industrial City in Alborz Province and Yaftabad. The integrated portfolio spans prevention through vaccination (Pentavalent and quadrivalent HPV vaccines), biosimilar therapies (Interferon Beta-1a for multiple sclerosis), and specialized peptide injectables for cardiovascular, oncology, hematology, infectious disease, and musculoskeletal indications. Products are sold to the Iran Ministry of Health, hospitals, specialty clinics, and wholesale pharmaceutical distributors domestically, with planned exports to MENA markets.

Product overview

BioSun Pharmed is a knowledge-based biopharmaceutical company and subsidiary of Barekat Pharmaceutical Group, operating under the motto 'The Chain from Prevention to Treatment.' The company's integrated product portfolio comprises three main categories: (1) Vaccines including Gardisun (quadrivalent HPV vaccine) and Sunopent/Pentavalent (five-in-one childhood vaccine); (2) Biosimilar drugs including Sunrif (Interferon beta-1a for MS treatment); and (3) Peptide drugs including Suntegrilin (cardiovascular), Sun B Som (antifungal), Santorlin (oncology/endocrinology), Sanotide (hematology), and Relixosan (musculoskeletal). The products span therapeutic areas including neurology/MS, cardiovascular diseases, hematology, oncology, infectious diseases, and prevention through vaccination.

Differentiator

Problem solved

Functional benefit

Brands

• Barekat Pharmaceutical Group: Parent pharmaceutical group under which Biosun Pharmed operates as a subsidiary
• Biosun Darou
• Barekat Pharmaceutical Industrial City

Products and services

• Sunopent (Pentavalent Vaccine) Five-in-one combined vaccine protecting infants against Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae type b (Hib), administered via intramuscular injection in three primary doses plus one booster dose. Sold to the Iran Ministry of Health for the national childhood immunization program at approximately 6 million annual doses.
• Gardisun (Quadrivalent HPV Vaccine) Quadrivalent HPV vaccine preventing infection caused by four HPV types (6, 11, 16, 18), protecting against genital warts, precancerous cervical lesions, and cervical cancer. Supplied in 0.5 ml pre-filled syringes for intramuscular injection, intended for women and adolescents aged 9-26.
• Sunrif (Interferon Beta-1a Biosimilar) Interferon beta-1a liquid formulation biosimilar for Multiple Sclerosis treatment that reduces frequency and severity of clinical relapses and delays progression of physical disability. Distributed to MS patients with insurance reimbursement limiting out-of-pocket cost to 5–10 percent.
• Suntegrilin (Eptifibatide Injection) Eptifibatide 20 mg/10 ml injection for cardiovascular treatments; GP IIb/IIIa receptor inhibitor used for unstable angina, NSTE-ACS, and prevention of thrombosis during or after PCI. Distributed directly to hospitals and specialty clinics.
• Sun B Som (Liposomal Amphotericin B) Liposomal Amphotericin B 50 mg for injection; antifungal medication for severe invasive fungal infections including Invasive Candidiasis and Invasive Aspergillosis, with reduced renal toxicity compared to conventional Amphotericin B. Sold to hospitals and specialty clinical settings.
• Santorlin (Triptorelin Acetate) Triptorelin Acetate 3.75 mg sustained-release lyophilized powder for injection; GnRH agonist for treatment of advanced prostate cancer, uterine fibroids, endometriosis, and Central Precocious Puberty in children. Distributed to hospitals and specialty clinics.
• Sanotide (Actronide Acetate) Actronide Acetate 30 mg lyophilized injection for Hemophilia A patients with Factor VIII inhibitors; bypassing agent that activates the coagulation pathway independently of Factor VIII to manage bleeding. Sold to hospitals.
• Relixosan (Camphor and Menthol Topical Gel) Topical gel with Camphor and Menthol for relief of musculoskeletal pain, muscle spasms, and neck, back, and shoulder pain; increases local blood flow and provides a cooling sensation. Sold through pharmaceutical distribution networks.

Quantifiable outcome

• Approximately 6 million annual doses of the Pentavalent vaccine supplied to Iran's national immunization program, with capacity for several times this amount for export
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Barakat Pharmaceutical Holding Co.coreStrategic or Co-development PartnerBarakat Pharmaceutical Holding Co. is the parent company of Biosun Pharmed. Biosun Pharmed operates as a subsidiary under the Barekat Pharmaceutical Group, utilizing shared infrastructure including the Barekat Pharmaceutical Industrial City. The parent company provides strategic direction, investment, and integrated pharmaceutical ecosystem support, with Biosun Pharmed focusing on R&D and production of biosimilars, vaccines, monoclonal antibodies, and peptide drugs.
• Tehran University of Medical Sciences (TUMS)supportingStrategic or Co-development PartnerBiosun Pharmed maintains close cooperation with Tehran University of Medical Sciences and its Faculty of Pharmacy for educational collaborations, research support, and clinical trial capabilities. The company utilizes expertise from prominent pharmacy professors in its management and advisory teams.
• Various Medical Universities Across IransupportingStrategic or Co-development PartnerBiosun Pharmed collaborates with several medical universities across Iran beyond TUMS for educational workshops, MS treatment conferences in cities including Mashhad, Tehran, Urmia, Ahvaz, Arak, Tabriz, and Rasht, and broader scientific community engagement.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing finished dosage forms including injectables and biosimilars for the MENA region. Comparable as a regional MENA pharma manufacturer competing for the same hospital and tender opportunities.
• SPIMACO (Saudi Pharmaceutical Industries): Saudi Arabia's leading pharmaceutical manufacturer with branded generics and biologics. Comparable as a regional MENA-focused pharma with vaccine ambitions and government procurement relationships similar to Biosun's domestic model.

Direct peers

• AryoGen Pharmed: Iranian specialty biosimilar manufacturer (founded under similar state-linked origins) producing monoclonal antibodies and biosimilars in oncology and immunology. Direct competitor in Iran's domestic biosimilar and specialty biologic market with overlapping therapeutic areas.
• Sobhan Oncology: Iranian biotech focused on oncology biologics including monoclonal antibodies. Overlaps directly with Biosun's oncology peptide portfolio (Santorlin/Triptorelin) and Iranian market positioning for hospital-administered biologics.
• Darou Pakhsh Pharmaceutical: One of the largest Iranian pharmaceutical manufacturers with a broad portfolio including biologics, vaccines, and finished dosage forms. Comparable in scale, domestic market positioning, and parent-group (state-linked) ownership structure.
• Tehran Pharma Co. (TPICO): Major Iranian pharmaceutical producer of finished dosage forms across multiple therapeutic categories. Comparable as a domestic Iranian specialty/general pharma manufacturer serving similar hospital and pharmacy channels.

Broad incumbents

• Celltrion: South Korean biosimilar leader producing monoclonal antibody biosimilars globally. Comparable as an advanced biosimilar manufacturer whose competition defines pricing pressure on Biosun's Interferon Beta-1a and biosimilar portfolio.
• Hikma Pharmaceuticals: MENA-headquartered specialty pharmaceutical company with generic injectable, biosimilar, and branded specialty offerings. Comparable as a regional specialty pharma exporter operating across the same MENA target markets as Biosun's expansion plan.
• Bharat Biotech: Indian vaccine manufacturer producing combination pediatric vaccines (Pentavalent-class) and novel VLP-based vaccines globally. Comparable as a manufacturer in the same Pentavalent/HPV vaccine categories that compete for emerging-market tenders.
• Sinopharm (CNBG): China's largest state-linked vaccine and biologics manufacturer with global emerging-market vaccine distribution. Comparable in scale, state affiliation, vaccine portfolio breadth, and emerging-market export orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biosun-pharmed
• Facebooken.biosunpharmed.com/news/iran-joins-the-manufacturers

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSun Pharmed